Comparison of neoadjuvant nab-paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma.
Paclitaxel esophageal squamous cell carcinoma
immunotherapy
nab-
paclitaxel
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
26
12
2022
received:
16
11
2022
accepted:
28
12
2022
pubmed:
16
2
2023
medline:
7
3
2023
entrez:
15
2
2023
Statut:
ppublish
Résumé
This study aimed to compare the feasibility of nab-paclitaxel plus platinum-based chemotherapy (nabTP) versus paclitaxel plus platinum-based chemotherapy (TP) with immune checkpoint inhibitors (ICIs) as a neoadjuvant modality for locally resectable esophageal squamous cell carcinoma (ESCC). Between April 2019 and March 2022, we identified ESCC patients who received neoadjuvant immunotherapy with both nabTP (n = 213) and TP (n = 98) at our institution and Henan Cancer Hospital. The patients in the ICIs-nabTP and ICIs-TP groups were pair-matched (1:1) for tumor location, sex, smoking, drinking, clinical T and N stage. The primary endpoint was the hazard of 30-day major postoperative complications. Second, logistic models were applied to estimate the risk factors for pathological complete response (pCR) rate. All patients underwent esophagectomy with R0 resection. A statistically significant increase in the risk of developing major pulmonary (odds ratio [OR], 1.182; 95% confidence interval [CI]: 0.530-2.635; p = 0.683), anastomotic (OR, 1.881; 95% CI: 0.607-5.830; p = 0.267), cardiac (OR, 1.000; 95% CI: 0.426-2.349; p = 1.000) complications after neoadjuvant immunotherapy plus nabTP was not observed. The median interval to surgery was 39 days in the ICIs-nabTP group versus 44 days in the ICIs-TP group (p = 0.119). There was no 30-day mortality in each group. However, there was a slight difference in the 30-day readmission rate (p = 0.043) and the incidence of hydropneumothorax (p = 0.027) between the two groups. The pCR rates of the ICIs-nabTP and ICIs-TP group were 36.7 and 21.4%, respectively (p = 0.018). It appears to be feasible to add immunotherapy to nabTP regimen for locally advanced ESCC. Compared with TP, nabTP plus ICIs can achieve a better pCR rate in ESCC.
Sections du résumé
BACKGROUND
This study aimed to compare the feasibility of nab-paclitaxel plus platinum-based chemotherapy (nabTP) versus paclitaxel plus platinum-based chemotherapy (TP) with immune checkpoint inhibitors (ICIs) as a neoadjuvant modality for locally resectable esophageal squamous cell carcinoma (ESCC).
METHODS
Between April 2019 and March 2022, we identified ESCC patients who received neoadjuvant immunotherapy with both nabTP (n = 213) and TP (n = 98) at our institution and Henan Cancer Hospital. The patients in the ICIs-nabTP and ICIs-TP groups were pair-matched (1:1) for tumor location, sex, smoking, drinking, clinical T and N stage. The primary endpoint was the hazard of 30-day major postoperative complications. Second, logistic models were applied to estimate the risk factors for pathological complete response (pCR) rate.
RESULTS
All patients underwent esophagectomy with R0 resection. A statistically significant increase in the risk of developing major pulmonary (odds ratio [OR], 1.182; 95% confidence interval [CI]: 0.530-2.635; p = 0.683), anastomotic (OR, 1.881; 95% CI: 0.607-5.830; p = 0.267), cardiac (OR, 1.000; 95% CI: 0.426-2.349; p = 1.000) complications after neoadjuvant immunotherapy plus nabTP was not observed. The median interval to surgery was 39 days in the ICIs-nabTP group versus 44 days in the ICIs-TP group (p = 0.119). There was no 30-day mortality in each group. However, there was a slight difference in the 30-day readmission rate (p = 0.043) and the incidence of hydropneumothorax (p = 0.027) between the two groups. The pCR rates of the ICIs-nabTP and ICIs-TP group were 36.7 and 21.4%, respectively (p = 0.018).
CONCLUSIONS
It appears to be feasible to add immunotherapy to nabTP regimen for locally advanced ESCC. Compared with TP, nabTP plus ICIs can achieve a better pCR rate in ESCC.
Identifiants
pubmed: 36788648
doi: 10.1111/1759-7714.14795
pmc: PMC9981310
doi:
Substances chimiques
130-nm albumin-bound paclitaxel
0
Cisplatin
Q20Q21Q62J
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
700-708Informations de copyright
© 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Thorac Cancer. 2023 Mar;14(7):700-708
pubmed: 36788648
Eur J Cancer. 2021 Feb;144:232-241
pubmed: 33373868
J Clin Oncol. 2009 Oct 20;27(30):5062-7
pubmed: 19770374
J Clin Oncol. 2020 Dec 10;38(35):4138-4148
pubmed: 33026938
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Clin Oncol. 2014 Aug 10;32(23):2416-22
pubmed: 24982463
Cancer. 2011 Apr 15;117(8):1704-10
pubmed: 21472717
Lancet Oncol. 2019 Nov;20(11):1506-1517
pubmed: 31582355
Anticancer Res. 2018 Dec;38(12):6809-6814
pubmed: 30504394
J Clin Oncol. 2018 Sep 20;36(27):2796-2803
pubmed: 30089078
J Natl Compr Canc Netw. 2019 Jul 1;17(7):855-883
pubmed: 31319389
J Immunother Cancer. 2022 Mar;10(3):
pubmed: 35338088
N Engl J Med. 2012 May 31;366(22):2074-84
pubmed: 22646630
Clin Cancer Res. 2006 Feb 15;12(4):1317-24
pubmed: 16489089
J Clin Oncol. 2011 Dec 1;29(34):4548-54
pubmed: 21969517
JAMA Oncol. 2019 Apr 01;5(4):546-550
pubmed: 30570649
Neoplasia. 2011 Apr;13(4):327-38
pubmed: 21472137
Oncogene. 2021 Sep;40(35):5367-5378
pubmed: 34272474
Onco Targets Ther. 2013 May 27;6:585-91
pubmed: 23737672
J Immunother Cancer. 2022 Jan;10(1):
pubmed: 35022193
Science. 2020 Jan 31;367(6477):
pubmed: 32001626
Int J Cancer. 2022 Jul 1;151(1):128-137
pubmed: 35188268
J Thorac Dis. 2018 Jul;10(7):4069-4076
pubmed: 30174850
Lancet Oncol. 2011 Jul;12(7):681-92
pubmed: 21684205
Clin Cancer Res. 2021 Jun 15;27(12):3351-3359
pubmed: 33504550
Lancet Oncol. 2010 Sep;11(9):835-44
pubmed: 20692872
Br J Anaesth. 2014 Jul;113 Suppl 1:i68-73
pubmed: 24583820
Future Oncol. 2019 Apr;15(10):1057-1066
pubmed: 30735435
Clin Cancer Res. 2019 Oct 1;25(19):5743-5751
pubmed: 31040150
J Clin Oncol. 2012 Jun 10;30(17):2055-62
pubmed: 22547591
World J Gastroenterol. 2010 Apr 7;16(13):1649-54
pubmed: 20355244
Onco Targets Ther. 2016 Sep 23;9:5663-5669
pubmed: 27713635
Int J Surg. 2022 Jul;103:106680
pubmed: 35595021
Gynecol Oncol. 2011 Jul;122(1):111-5
pubmed: 21497382
J Cancer. 2016 Jan 08;7(3):268-75
pubmed: 26918039
Oncotarget. 2016 Aug 2;7(31):50624-50634
pubmed: 27244882
Lancet Oncol. 2015 Sep;16(9):1090-1098
pubmed: 26254683
Lancet Oncol. 2017 Sep;18(9):1249-1260
pubmed: 28784312
BMC Cancer. 2011 May 19;11:181
pubmed: 21595951
Lancet. 2002 May 18;359(9319):1727-33
pubmed: 12049861
Oncologist. 2022 Feb 3;27(1):e18-e28
pubmed: 35305102